Jeffrey Goldberg, MD, PhD
Advancing Cell Differentiation in Glaucoma
Published on:
What: This finding shows new potential for cell replacement treatments for glaucoma.
Where: “Opposing Effects of Growth and Differentiation Factors in Cell-Fate Specification,”Current Biology, 2019
BrightFocus Connection: Jeffrey Goldberg, MD, PhD, Stanford University, received a grant for this work from the BrightFocus Foundation’s National Glaucoma Research program.
Why It Is Important: Neurons of the eye, once damaged, do not replace themselves, which has led to scientific efforts to replace these neurons in glaucoma (RGCs) using stem cells for replacement therapy. This is particularly challenging as very few stem cells change into RGCs. Gaining a better understanding of what regulates the growth and differentiation of RGCs can improve the outcome of cell replacement therapy by directing the stem cells to become RGCs. This study reports a new mechanism that increases the likelihood of successfully transplanting RGCs, advancing cell-based replacement therapies.
-
- Jeffrey Goldberg 2015-20 NGR grant profile
- Volunteers Helping to Save Sight in Stanford Clinical Trial (2018)
- Developing a New Arsenal to Fight Glaucoma: Q&A (2016)
- Experimental Drugs May Help the Optic Nerve Fight Glaucoma (2016)
- Experimental Drug, Implanted in Eye, Could Fight Glaucoma (press release, 2016)
Donate to Glaucoma Disease Research
Your gift can help lead to treatments and a cure to end glaucoma. Fund the latest, promising research and help provide valuable information to families living with this disease.
Don't miss out
Receive Glaucoma Disease breakthrough news, research updates, and inspiring stories.